title: Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.
abstract: BACKGROUND
  The peritoneum is one of the most frequent sites of recurrent gastric carcinoma after curative treatment, despite the administration of pre- and/or postoperative systemic chemotherapy. Indeed, the prognosis of peritoneal carcinomatosis from gastric carcinoma continues to be poor, with a median survival of less than one year with systemic chemotherapy. Whereas the prognosis of peritoneal carcinomatosis from colorectal cancer has changed with the development of locally administered hyperthermic intraperitoneal chemotherapy (HIPEC), survival results following carcinomatosis from gastric cancer remain disappointing, yielding a 5-year survival rate of less than 20%. Innovative surgical therapies such as intraperitoneal immunotherapy therefore need to be developed for the immediate postoperative period after complete cytoreductive surgery. In a recent randomised study, a clinical effect was obtained after intraperitoneal infusion of catumaxomab in patients with malignant ascites, notably from gastric carcinoma. Catumaxomab, a nonhumanized chimeric antibody, is characterized by its unique ability to bind to three different types of cells: tumour cells expressing the epithelial cell adhesion molecule (EpCAM), T lymphocytes (CD3) and also accessory cells (Fcγ receptor). Because the peritoneum is an immunocompetent organ and up to 90% of gastric carcinomas express EpCAM, intraperitoneal infusion of catumaxomab after complete resection of all macroscopic disease (as defined in the treatment of carcinomatosis from colorectal cancer) could therefore efficiently treat microscopic residual disease.
  
  
  METHODS
  The aim of this randomized phase II study is to assess 2-year overall survival after complete resection of limited carcinomatosis synchronous with gastric carcinoma, followed by an intraperitoneal infusion of catumaxomab with different total doses administered in each of the 2 arms. Close monitoring of peri-opertive mortality, morbidity and early surgical re-intervention will be done with stopping rules. Besides this analysis, translational research will be conducted to determine immunological markers of catumaxomab efficacy and to correlate these markers with clinical efficacy.
authors.affiliation: Department of Surgical Oncology - Gustave Roussy, 114 rue Edouard Vaillant, Villejuif, Cedex 94805, France. goere@igr.fr.
authors.forename: Diane
authors.initials: D
authors.lastname: Goéré
authors.forename: Nathalie
authors.initials: N
authors.lastname: Gras-Chaput
authors.forename: Anne
authors.initials: A
authors.lastname: Aupérin
authors.forename: Caroline
authors.initials: C
authors.lastname: Flament
authors.forename: Christophe
authors.initials: C
authors.lastname: Mariette
authors.forename: Olivier
authors.initials: O
authors.lastname: Glehen
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
authors.forename: Dominique
authors.initials: D
authors.lastname: Elias
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D002985:Clinical Protocols; D006801:Humans; D007167:Immunotherapy; D007263:Infusions, Parenteral; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D018033:Antibodies, Bispecific; C522419:catumaxomab